Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VLA1701 ETEC Challenge Study
NCT03576183Phase 2Completed
- Sponsor
- Valneva
- Start
- Jun 2018
- Primary completion
- Jun 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of VLA1701 in enterotoxigenic Escherichia coli infection, sponsored by Valneva. Started Jun 2018; status: completed.
02
Drugs
VLA1701
03
Conditions
enterotoxigenic Escherichia coli infection
Beyond the preview
Go deeper on NCT03576183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03576183.